In Silico Drug Discovery Market Seen Surging to More Than $8B by 2030

The in silico drug discovery market is projected to grow at about 13% annually through 2030, driven by wider use of AI, machine learning and cloud computing in pharmaceutical research. North America is expected to lead the market, while NVIDIA remains the top player in a crowded field of computational drug discovery firms.

Why it matters: - In silico drug discovery is moving from a niche research tool to a meaningful part of pharmaceutical R&D, with the market forecast to top $8 billion by 2030. - Faster computing, AI models and cloud access are changing how drug makers identify targets, screen compounds and cut development costs. - The market still remains small relative to broader drug discovery and the global pharmaceutical industry, which means growth potential remains high.

What happened: - The Business Research Company released its The In Silico Drug Discovery Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 27, 2026. - The report projects the in silico drug discovery market will grow at a compound annual growth rate of about 13% through 2030. - The market is expected to exceed $8 billion by 2030. - North America is forecast to be the largest regional market in 2030 at $3.0 billion. - The United States is projected to be the largest country market at $2.7 billion in 2030.

The details: - The in silico segment is expected to account for about 7% of the broader small molecule drug discovery market, which is forecast to reach around $116 billion by 2030. - Within the larger pharmaceuticals industry, projected to hit $2,496 billion by 2030, in silico drug discovery would represent about 0.3% of total value. - North America is expected to grow from $1.6 billion in 2025 to $3.0 billion in 2030, a 13% CAGR. - The U.S. market is projected to rise from $1.5 billion in 2025 to $2.7 billion in 2030, also at 13% CAGR. - Software is expected to be the largest component, representing 61% of the market, or about $5 billion, in 2030. - The market covers on-premise and cloud deployment models. - Drug discovery applications in the report include target identification and validation, hit identification, lead optimization and candidate validation. - Therapeutic areas include oncology, neurology, cardiovascular disease, infectious diseases and metabolic disorders. - AI and machine learning are a major growth driver because they help identify targets, rank compounds and improve molecular design. - Cost and time pressures in drug development are also expanding demand for in silico approaches. - High-performance computing and cloud infrastructure are helping scale simulations, virtual screening and data analysis. - The software and services segments are expected to add more than $3 billion in value by 2030. - Between 2025 and 2030, software is expected to grow by $2 billion and services by $1 billion. - NVIDIA Corporation is the leading market player, with a 4% share of global sales in 2025. - Other major companies named in the report include Dassault Systèmes, Recursion Pharmaceuticals, Schrödinger, Owkin, Insilico Medicine, Simulations Plus, XtalPi, BenevolentAI and Iktos. - The top 10 players accounted for just 14% of total revenue in 2025, indicating a moderately fragmented market.

Between the lines: - The market structure suggests no single company has dominant control, which leaves room for newer AI platform providers and specialized drug discovery firms. - The report highlights a competitive shift toward platforms that combine generative AI, predictive analytics, multiomics data and cloud-based collaboration. - Insilico Medicine introduced Science MMAI Gym in January 2026, a training platform aimed at improving large language models for drug discovery using proprietary chemistry, biology and clinical datasets. - That kind of benchmarking and model-tuning tool points to a broader push for pharmaceutical-grade AI systems rather than generic AI models.

What's next: - Competition is likely to intensify as more drug developers adopt digital discovery workflows and look for faster lead selection and lower failure rates. - The biggest opportunity areas are expected to remain software and services, especially cloud-based tools, AI-driven design systems and high-performance computing. - Strategic partnerships between life sciences companies and technology providers are likely to expand as the market scales.

The bottom line: - In silico drug discovery is becoming a larger, more commercialized part of pharmaceutical innovation, with AI and computing power driving the next phase of growth.